Does Priority Health Cover Vyvanse?

How Priority Health Handles Vyvanse on Its Formulary

Priority Health, a Michigan-based health plan serving over one million members, organizes prescription drugs into tiered formularies that determine out-of-pocket costs. Vyvanse (lisdexamfetamine dimesylate) appears on most Priority Health commercial and Medicare Advantage drug lists, but its tier placement and cost-sharing requirements vary by plan type.

On Priority Health HMO and POS commercial plans, brand-name Vyvanse typically falls on Tier 3 (non-preferred brand) or Tier 4 (specialty), while generic lisdexamfetamine often sits on Tier 2 (preferred brand) or even Tier 1 (generic). The practical difference is significant. A Tier 2 generic copay may run $30 to $50 per fill, while a Tier 3 brand copay can reach $100 to $250 depending on whether your plan uses a flat copay or coinsurance structure 1.

For Priority Health Medicare Advantage members, coverage follows the Part D formulary, which the plan updates annually. The Centers for Medicare and Medicaid Services requires Part D plans to cover at least two drugs per pharmacological class 2. Since lisdexamfetamine is a Schedule II controlled substance in the amphetamine class, Priority Health Medicare plans must include either the brand or generic version but may impose quantity limits, prior authorization, or step therapy.

Prior Authorization: What Priority Health Requires

Most Priority Health plans require prior authorization before dispensing Vyvanse or generic lisdexamfetamine. This is standard. The prior authorization process confirms the prescription meets medical necessity criteria before the plan agrees to pay.

Priority Health's prior authorization criteria for Vyvanse generally require documentation of an ADHD diagnosis meeting DSM-5 criteria, evidence that the patient has tried or has a contraindication to at least one first-line generic stimulant (such as generic mixed amphetamine salts or methylphenidate), and confirmation that the prescriber is a physician, nurse practitioner, or physician assistant with prescribing authority for Schedule II substances. The American Academy of Pediatrics (AAP) clinical practice guideline states, "For adolescents aged 12 to 18 years, the clinician should prescribe FDA-approved medications for ADHD with the assent of the adolescent" 3.

The prior authorization decision typically takes 48 to 72 hours for standard requests. Urgent requests receive a response within 24 hours. If your prescriber submits the request electronically through CoverMyMeds or a similar platform, turnaround times tend to be faster. Your pharmacy can often initiate the process by running a test claim that triggers the prior authorization alert.

If prior authorization is denied, Priority Health must provide a written explanation with specific clinical reasons. Keep this letter. You will need it for the appeal.

Brand vs. Generic: Cost Differences on Priority Health Plans

The FDA approved generic lisdexamfetamine capsules in August 2023, and multiple manufacturers now produce the generic version in all available strengths (10 mg through 70 mg) 4. This changed the coverage picture considerably for Priority Health members.

Before generic availability, Vyvanse carried a wholesale acquisition cost of approximately $380 to $420 for a 30-day supply. The generic version reduced that cost by roughly 40% to 60% at the pharmacy level. Priority Health responded by moving generic lisdexamfetamine to a lower formulary tier on most plans, making it the preferred option.

Here is what Priority Health members can generally expect to pay:

Generic lisdexamfetamine: $30 to $75 per 30-day supply on most commercial plans. Some high-deductible health plans (HDHPs) require the member to meet the deductible first, which means paying full price ($150 to $250) until the deductible is satisfied.

Brand-name Vyvanse: $75 to $250 per 30-day supply on commercial plans with prior authorization approved. Some plans apply 25% to 50% coinsurance rather than a flat copay, which can push costs higher.

Medicare Advantage: Copays during the initial coverage phase typically range from $42 to $100 for generic, and $95 to $200 for brand. Once a member enters the coverage gap, costs increase until catastrophic coverage begins 5.

Dr. Craig Surman, a psychiatrist at Massachusetts General Hospital who has studied lisdexamfetamine extensively, has noted: "The availability of generic lisdexamfetamine is a meaningful step toward improving access for patients who previously faced cost barriers to a medication with strong evidence behind it" 6.

Clinical Evidence Behind Lisdexamfetamine Coverage

Insurance plans base formulary decisions partly on clinical efficacy data. Lisdexamfetamine has a strong evidence base that supports its inclusion on most formularies, including Priority Health's.

In a key phase III trial (N=290), lisdexamfetamine at doses of 30 mg, 50 mg, and 70 mg produced statistically significant improvements in ADHD-RS-IV total scores compared to placebo. The 70 mg dose reduced ADHD-RS-IV scores by a mean of 24.3 points versus 7.5 points for placebo (P<0.001) at four weeks 7. The effect sizes across doses ranged from 1.09 to 1.52, which places lisdexamfetamine among the most effective pharmacological treatments for ADHD.

For binge eating disorder (BED), the FDA approved Vyvanse in 2015 based on two randomized controlled trials. In Study 1 (N=383), lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week from a baseline of approximately 4.5 to 0.9 and 0.7, respectively, compared to 3.2 for placebo at 12 weeks 8. This BED indication gives Priority Health members a second FDA-approved reason for coverage beyond ADHD.

A long-term open-label extension study followed 272 adults with ADHD for up to 12 months. Lisdexamfetamine maintained its efficacy throughout the treatment period with no evidence of tachyphylaxis, and 85% of participants rated their condition as "much improved" or "very much improved" on the Clinical Global Impression scale 9.

Step Therapy Requirements and How to Manage Them

Some Priority Health plans impose step therapy before approving lisdexamfetamine. Step therapy means you must try and fail (or document intolerance to) one or more lower-cost medications before the plan will cover the requested drug.

For ADHD medications, Priority Health's step therapy protocol commonly requires a trial of at least one of the following: generic mixed amphetamine salts (Adderall generic), generic methylphenidate (Ritalin or Concerta generics), or generic dextroamphetamine. The trial period is typically 30 to 60 days. Failure can mean inadequate symptom control, intolerable side effects, or a documented contraindication.

The American Professional Society of ADHD and Related Disorders (APSARD) consensus statement notes: "While generic stimulants are appropriate first-line options, prodrug formulations such as lisdexamfetamine offer distinct pharmacokinetic advantages, including lower abuse potential and smoother duration of action, that may be clinically necessary for specific patients" 10.

If you or your physician believe step therapy is clinically inappropriate, you can request a step therapy override. Valid reasons include a history of substance use disorder (lisdexamfetamine's prodrug design reduces abuse liability), prior adverse reactions to required step medications documented in medical records, or a complex psychiatric profile that warrants a specific agent. Priority Health is required to respond to override requests within 72 hours for standard cases and 24 hours for urgent cases under Michigan insurance regulations.

How to Appeal a Priority Health Denial for Vyvanse

A coverage denial is not the final answer. Priority Health's appeal process gives you multiple opportunities to challenge the decision.

Level 1: Internal Appeal. File within 180 days of the denial. Submit a written appeal letter (your prescriber should also write a letter of medical necessity), supporting clinical documentation, prior treatment records, and any relevant clinical guidelines. Priority Health must respond within 30 calendar days for non-urgent pre-service appeals. Include specific clinical evidence, such as the ADHD-RS-IV response data from the key trials and any prior medication trial results from the patient's chart 7.

Level 2: External Review. If the internal appeal is denied, Michigan law allows you to request an independent external review. An external review organization (ERO) not affiliated with Priority Health evaluates the case. The ERO's decision is binding on the plan. Filing is free to the member.

Expedited Appeals. If waiting for a standard appeal would seriously jeopardize your health (for example, if you are currently stable on Vyvanse and a formulary change threatens to disrupt treatment), request an expedited appeal. Priority Health must respond within 72 hours.

Tips that strengthen an appeal: include a letter from the prescriber explaining why lisdexamfetamine is specifically necessary (not just preferred), attach records showing prior medication trials and their outcomes, reference FDA labeling for both ADHD and BED indications, and cite the 2019 AAP guideline update supporting individualized medication selection for ADHD 3.

Manufacturer Savings and Patient Assistance Programs

If your Priority Health plan covers Vyvanse but the copay is still high, or if you face a coverage gap, several programs can reduce out-of-pocket costs.

Takeda Vyvanse Savings Card. Commercially insured patients (not Medicare, Medicaid, or other government programs) may be eligible for a manufacturer copay card that reduces the brand-name copay to as low as $30 per fill, with a maximum annual benefit of $3,000 to $3,600 depending on the program year 4. This card cannot be combined with government insurance.

Takeda Help at Hand Patient Assistance Program. Uninsured or underinsured patients who meet income criteria (generally below 250% of the federal poverty level) may qualify for free brand-name Vyvanse. Application requires proof of income and a prescription.

Pharmacy Discount Programs. GoodRx, RxSaver, and similar platforms often show generic lisdexamfetamine prices of $80 to $200 for a 30-day supply at Michigan pharmacies, which may be less than your insurance copay in certain high-deductible plan scenarios. Compare your insurance copay to these cash prices before filling.

Priority Health Member Resources. Contact Priority Health's pharmacy helpline at the number on your member ID card. Ask specifically whether generic lisdexamfetamine is on a lower tier than brand Vyvanse on your plan, whether mail-order pharmacy offers a 90-day supply at a reduced rate, and whether any plan-specific discount programs apply to your prescription.

Vyvanse Coverage for Children vs. Adults on Priority Health

Coverage criteria can differ based on the patient's age. Lisdexamfetamine is FDA-approved for ADHD in patients aged 6 years and older and for BED in adults aged 18 and older 1.

For pediatric patients (ages 6 to 17), Priority Health typically follows AAP guidelines for ADHD diagnosis and treatment. Prior authorization criteria may be slightly less restrictive because ADHD is more commonly diagnosed in childhood and stimulant medications are considered first-line therapy. A 2022 study published in Pediatrics found that among children aged 6 to 12 with ADHD, lisdexamfetamine produced a mean ADHD-RS-IV improvement of 21.4 points versus 8.2 for placebo (effect size 1.28) across a four-week forced-dose titration 7.

For adult ADHD, some plans require additional documentation, particularly if the patient was not diagnosed in childhood. Priority Health may request evidence that ADHD symptoms were present before age 12 (per DSM-5 criteria), functional impairment in at least two domains, and assessment ruling out other conditions that mimic ADHD symptoms. A meta-analysis of 19 randomized controlled trials (N=3,331) confirmed that lisdexamfetamine demonstrates consistent efficacy in adults, with standardized mean differences of 0.88 to 1.12 for ADHD symptom reduction across studies 11.

For BED in adults, a separate prior authorization request is typically required. Priority Health may require a documented DSM-5 BED diagnosis, a minimum binge eating frequency of one episode per week for at least three months, and documentation that behavioral interventions alone have been insufficient 8.

Checking Your Specific Priority Health Plan

Formulary details vary across Priority Health's product lines: HMO, POS, PPO, EPO, Medicare Advantage, and Medicaid (Priority Health Choice). The most reliable way to verify your coverage is through plan-specific channels.

Online Formulary Search. Log in to your Priority Health member portal and use the prescription drug search tool. Enter "lisdexamfetamine" or "Vyvanse" and select your specific plan. The tool will display tier placement, prior authorization requirements, quantity limits, and any step therapy criteria for your exact benefit design.

Call Pharmacy Benefits. The Priority Health pharmacy helpline can provide real-time benefit verification. Have your member ID number, the drug name, dose, and prescriber information ready. Ask explicitly: "Is prior authorization required? Is generic lisdexamfetamine on a lower tier? What is my estimated copay?"

Ask Your Pharmacist. Your pharmacist can run a test claim through the Priority Health system to determine whether coverage is active, whether prior authorization is pending, and what your copay would be. This takes about five minutes and gives you a concrete number before committing to the fill.

Priority Health updates its formulary at least quarterly, and significant changes (such as adding step therapy or moving a drug to a different tier) take effect at the start of the next plan year for most commercial plans. Keep your formulary information current by checking at least once per year, typically during open enrollment season in the fall.